19 research outputs found
Hepatic safety of antibiotics used in primary care
Antibiotics used by general practitioners frequently appear in adverse-event reports of drug-induced hepatotoxicity. Most cases are idiosyncratic (the adverse reaction cannot be predicted from the drug's pharmacological profile or from pre-clinical toxicology tests) and occur via an immunological reaction or in response to the presence of hepatotoxic metabolites. With the exception of trovafloxacin and telithromycin (now severely restricted), hepatotoxicity crude incidence remains globally low but variable. Thus, amoxicillin/clavulanate and co-trimoxazole, as well as flucloxacillin, cause hepatotoxic reactions at rates that make them visible in general practice (cases are often isolated, may have a delayed onset, sometimes appear only after cessation of therapy and can produce an array of hepatic lesions that mirror hepatobiliary disease, making causality often difficult to establish). Conversely, hepatotoxic reactions related to macrolides, tetracyclines and fluoroquinolones (in that order, from high to low) are much rarer, and are identifiable only through large-scale studies or worldwide pharmacovigilance reporting. For antibiotics specifically used for tuberculosis, adverse effects range from asymptomatic increases in liver enzymes to acute hepatitis and fulminant hepatic failure. Yet, it is difficult to single out individual drugs, as treatment always entails associations. Patients at risk are mainly those with previous experience of hepatotoxic reaction to antibiotics, the aged or those with impaired hepatic function in the absence of close monitoring, making it important to carefully balance potential risks with expected benefits in primary care. Pharmacogenetic testing using the new genome-wide association studies approach holds promise for better understanding the mechanism(s) underlying hepatotoxicity
Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? – study protocol for a randomized controlled trial [NCT00120978]
Background:
Systemic inflammation is associated with various complications in chronic obstructive pulmonary disease including weight loss, cachexia, osteoporosis, cancer and cardiovascular diseases. Inhaled corticosteroids attenuate airway inflammation, reduce exacerbations, and improve mortality in chronic obstructive pulmonary disease. Whether inhaled corticosteroids by themselves or in combination with a long-acting β2-adrenoceptor agonist repress systemic inflammation in chronic obstructive pulmonary disease is unknown. The Advair Biomarkers in COPD (ABC) study will determine whether the effects of inhaled corticosteroids alone or in combination with a long-acting β2-adrenoceptor agonist reduce systemic inflammation and improve health status in patients with chronic obstructive pulmonary disease.
Methods/Design
After a 4-week run-in phase during which patients with stable chronic obstructive pulmonary disease will receive inhaled fluticasone (500 micrograms twice daily), followed by a 4-week withdrawal phase during which all inhaled corticosteroids and long acting β2-adrenoceptor agonists will be discontinued, patients will be randomized to receive fluticasone (500 micrograms twice daily), fluticasone/salmeterol combination (500/50 micrograms twice daily), or placebo for four weeks. The study will recruit 250 patients across 11 centers in western Canada. Patients must be 40 years of age or older with at least 10 pack-year smoking history and have chronic obstructive pulmonary disease defined as forced expiratory volume in one second to vital capacity ratio of 0.70 or less and forced expiratory volume in one second that is 80% of predicted or less. Patients will be excluded if they have any known chronic systemic infections, inflammatory conditions, history of previous solid organ transplantation, myocardial infarction, or cerebrovascular accident within the past 3 months prior to study enrolment. The primary end-point is serum C-reactive protein level. Secondary end-points include circulating inflammatory cytokines such as interleukin-6 and interleukin-8 as well as health-related quality of life and lung function.
Discussion
If inhaled corticosteroids by themselves or in combination with a long-acting β2-adrenoceptor agonist could repress systemic inflammation, they might greatly improve clinical prognosis by reducing various complications in chronic obstructive pulmonary disease.Medicine, Department ofMedicine, Faculty ofRespiratory Medicine, Division ofNon UBCReviewedFacult
Clinical Practice Guideline for Solid Organ Donation and Transplantation During the COVID-19 Pandemic
Background. The coronavirus 2019 (COVID-19) pandemic has disrupted health systems worldwide, including solid
organ donation and transplantation programs. Guidance on how best to screen patients who are potential organ donors
to minimize the risks of COVID-19 as well as how best to manage immunosuppression and reduce the risk of COVID-19
and manage infection in solid organ transplant recipients (SOTr) is needed. Methods. Iterative literature searches were
conducted, the last being January 2021, by a team of 3 information specialists. Stakeholders representing key groups
undertook the systematic reviews and generation of recommendations using a rapid response approach that respected
the Appraisal of Guidelines for Research and Evaluation II and Grading of Recommendations, Assessment, Development
and Evaluations frameworks. Results. The systematic reviews addressed multiple questions of interest. In this guidance
document, we make 4 strong recommendations, 7 weak recommendations, 3 good practice statements, and 3 statements
of “no recommendation.” Conclusions. SOTr and patients on the waitlist are populations of interest in the COVID-19
pandemic. Currently, there is a paucity of high-quality evidence to guide decisions around deceased donation assessments
and the management of SOTr and waitlist patients. Inclusion of these populations in clinical trials of therapeutic interventions,
including vaccine candidates, is essential to guide best practices.Medicine, Faculty ofPharmaceutical Sciences, Faculty ofNon UBCInfectious Diseases, Division ofMedicine, Department ofReviewedFacultyResearcherGraduat